MedTrace Logo

A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

NCT05452239 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 608

Last updated 2026-01-29

Study results available
· View outcomes & findings →

Summary

Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins). Treatment of MOH usually involves reducing the dose of or discontinuing acute medications.

Eptinezumab is a medication used for the preventive treatment of migraine in adults. The main goals of this trial are to learn whether eptinezumab helps reduce the number of days with migraine, the number of days with headache, and acute medication use in adults who have migraine and MOH.

Conditions

Interventions

DRUG

Eptinezumab

Solution for infusion

DRUG

Placebo

Solution for infusion

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2024-10-22
Completion
2025-03-13
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Denmark
  • France
  • Georgia
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05452239 on ClinicalTrials.gov